-
Avenue Therapeutics NASDAQ:ATXI Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City and was founded by Fortress Biotech, Inc.
Location: 2 Gansevoort St Fl 9, New York, 10014-1667, US | Website: www.avenuetx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-2.886M
Cash
4.919M
Avg Qtr Burn
-2.147M
Short % of Float
1.18%
Insider Ownership
13.16%
Institutional Own.
8.13%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IV Tramadol Details Pain, Post operative acute pain | Phase 3 Initiation | |
BAER-101 Details Anxiety Disorders, Epilepsy | Phase 2a Initiation | |
AJ201 Details Spinal and bulbar muscular atrophy , Spinocerebellar Ataxia, Huntington's disease, Kennedy's Disease | Phase 1/2 Data readout |